Zobrazeno 1 - 10
of 44
pro vyhledávání: '"S. Oh"'
Autor:
Albert Eusik Kim, Ken Chang, Kyrre E. Emblem, Jayashree Kalpathy-Cramer, Eudocia Quant Lee, Nancy U. Lin, Sara M. Tolaney, Lakshmi Nayak, Ugonma Nnenna Chukwueke, Kevin S. Oh, Helen Alice Shih, Michael White, Don P. Lawrence, Beverly Moy, Justine Vanessa Cohen, Anita Giobbie-Hurder, Daniel P. Cahill, Ryan J. Sullivan, Priscilla Kaliopi Brastianos, Elizabeth Robins Gerstner
Publikováno v:
Journal of Clinical Oncology. 39:3059-3059
3059 Background: Immune checkpoint inhibitors (ICI) have recently been shown to be effective for brain metastases (BM) in melanoma and lung cancer. Several studies demonstrate that 20-50% of BM patients respond to ICI. The reasons behind this wide va
Autor:
Ugonma Chukwueke, Lakshmi Nayak, Anita Giobbie-Hurder, Priscilla Kaliopi Brastianos, Jayashree Kalpathy-Cramer, Kevin S. Oh, Helen A. Shih, Justine V. Cohen, Daniel P. Cahill, Michael White, Sara M. Tolaney, Beverly Moy, Ken Chang, Albert E. Kim, Nan Lin, Kyrre E. Emblem, D. P. Lawrence, Ryan J. Sullivan, Elizabeth R. Gerstner, Eudocia Q. Lee
Publikováno v:
Journal of Clinical Oncology. 38:2529-2529
2529 Background: Immune checkpoint inhibitors (ICI) have recently been shown to be effective for brain metastases (BM) for melanoma and lung cancer. This breakthrough has prompted interest in evaluating ICI in BM of other histologies. However, accura
Autor:
Nancy Wang, Nathaniel Goss, Priscilla Kaliopi Brastianos, Mia Bertalan, Kevin S. Oh, Maura Keeley, Justine V. Cohen, Daniel P. Cahill
Publikováno v:
Journal of Clinical Oncology. 37:e13585-e13585
e13585 Background: Brain metastases are the most common tumors to affect the central nervous system. Treatment options have recently evolved with the use of targeted therapies, immunotherapy, and increased clinical trials availability. We describe ou
Autor:
John C Spinosa, Alex Robertson, Abhik Shah, Michael S. Oh, Ken Nesmith, Neil Peterman, Andrew M. Davis, Timothy R. Wilson, Nicole J. Lambert, Wade T. Iams, Haluk Tezcan, Young Kwang Chae, Becky Wong, Rohith Srivas, Ayse Tezcan, Peter George, David Chan, Robert W. Lentz, Ram Yalamanchili
Publikováno v:
Journal of Clinical Oncology. 37:3041-3041
3041 Background: Liquid biopsies have potential clinical utility as dynamic biomarkers for treatment response. We analyzed serial changes in whole-genome (WG) cfDNA to identify patients with disease progression prior to routine imaging. Methods: We p
Autor:
Haluk Tezcan, Neil Peterman, Ken Nesmith, Abhik Shah, Timothy R. Wilson, Peter George, Andrew M. Davis, Wade T. Iams, Young Kwang Chae, Haleigh Wood, Nicole J. Lambert, Michael S. Oh, Alex Robertson, Ram Yalamanchili, Ayse Tezcan, John C Spinosa, Rohith Srivas, David Chan, Robert W. Lentz, Jason Close
Publikováno v:
Journal of Clinical Oncology. 37:3042-3042
3042 Background: Methylation is an epigenetic modification linked to cancer pathogenesis. The aim was to determine if changes in cfDNA methylation patterns before and after initiation of treatment could predict non-response to treatment prior to rout
Autor:
Robert W. Lentz, Michael S. Oh, Young Kwang Chae, Wade T. Iams, Andrew D. Hoffmann, Andrew M. Davis, Huiping Liu
Publikováno v:
Journal of Clinical Oncology. 37:e14044-e14044
e14044 Background: CTCs not only constitute a cellular component of liquid biopsy for dynamic, longitudinal information of malignancies, but also pose a continuous threat to seed new metastasis. Detection of these cells can help identify patients wit
Autor:
Elizabeth R. Gerstner, Anita Giobbie-Hurder, Nan Lin, Ryan J. Sullivan, Priscilla Kaliopi Brastianos, Eudocia Q. Lee, Michael White, Sara M. Tolaney, Sanjay M. Prakadan, Daniel P. Cahill, Alex K. Shalek, Kevin S. Oh, Andrew W. Navia, Ivanna Bihun, Justine V. Cohen, Ugonma Chukwueke, Christopher Alvarez-Breckenridge, Donald P. Lawrence, Lakshmi Nayak, Scott L. Carter
Publikováno v:
Journal of Clinical Oncology. 36:2007-2007
2007Background: Approximately 5-8% of patients with cancer develop leptomeningeal carcinomatosis (LMD). Median survival of patients with LMD is approximately 4-6 weeks and there are no effective tr...
Autor:
Priscilla K. Brastianos, William T. Curry, Devarati Mitra, David P. Ryan, Jennifer Y. Wo, Jeffrey W. Clark, Helen A. Shih, Ryan B. Corcoran, Kevin S. Oh, Theodore S. Hong, Jochen K. Lennerz, Aparna Raj Parikh
Publikováno v:
Journal of Clinical Oncology. 36:61-61
61 Background: HER2 amplification in gastrointestinal (GI) cancers, beyond gastric cancer, is uncommon and as a result infrequently tested. In breast cancer, HER2 amplification has been associated with brain metastases (BM) with associated prognostic
Autor:
Zhiyuan Hu, Charles M. Perou, Melissa A. Troester, Xiaping He, Junyuan Wu, Cheng Fan, Daniel S. Oh, Lisa A. Carey, Jerry Usary
Publikováno v:
Journal of Clinical Oncology. 24:1656-1664
Purpose The prognosis of a patient with estrogen receptor (ER) and/or progesterone receptor (PR) –positive breast cancer can be highly variable. Therefore, we developed a gene expression–based outcome predictor for ER+ and/or PR+ (ie, luminal) br
Publikováno v:
Journal of Clinical Oncology. 35:e13084-e13084
e13084 Background: To compare the incidence, mortality, and survival of head and neck cancer (HNCA) in the U.S. Hispanic population to other racial/ethnic groups. Methods: Using the National Cancer Institute’s Surveillance, Epidemiology, and End Re